BRIEF-Ideaya Biosciences Announces First-Patient-In For Phase 1 Combination Study Of Ide849, Dll3 Top1 Adc, And Ide161, Parg Inhibitor, In Dll3 Upregulated Solid Tumor Indications, Including Sclc, Nets, Necs, And Melanoma

Reuters03-30

March 30 (Reuters) - IDEAYA Biosciences Inc IDYA.O:

IDEAYA BIOSCIENCES ANNOUNCES FIRST-PATIENT-IN FOR PHASE 1 COMBINATION STUDY OF IDE849, DLL3 TOP1 ADC, AND IDE161, PARG INHIBITOR, IN DLL3 UPREGULATED SOLID TUMOR INDICATIONS, INCLUDING SCLC, NETS, NECS, AND MELANOMA
IDEAYA BIOSCIENCES INC - TARGETS CLINICAL DATA UPDATE FOR IDE849 AND IDE161 IN H2 2026

Source text: ID:nPn2gvj4Wa

Further company coverage: IDYA.O

((Reuters.Briefs@thomsonreuters.com;))

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2623348717?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-30 21:09","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2623348717","market":"nz","top_or_hot":-1,"title":"BRIEF-Ideaya Biosciences Announces First-Patient-In For Phase 1 Combination Study Of Ide849, Dll3 Top1 Adc, And Ide161, Parg Inhibitor, In Dll3 Upregulated Solid Tumor Indications, Including Sclc, Nets, Necs, And Melanoma","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-Ideaya Biosciences Announces First-Patient-In For Phase 1 Combination Study Of Ide849, Dll3 Top1 Adc, And Ide161, Parg Inhibitor, In Dll3 Upregulated Solid Tumor Indications, Including Sclc, Nets, Necs, And Melanoma</title></head><body><p><span>March 30 (Reuters)</span><span> - </span><a href=\"https://laohu8.com/S/IDYA\">IDEAYA Biosciences</a> Inc <span>IDYA.O</span>:</p><ul><li><p>IDEAYA BIOSCIENCES ANNOUNCES FIRST-PATIENT-IN FOR PHASE 1 COMBINATION STUDY OF IDE849, DLL3 TOP1 ADC, AND IDE161, PARG INHIBITOR, IN DLL3 UPREGULATED SOLID TUMOR INDICATIONS, INCLUDING SCLC, NETS, NECS, AND MELANOMA</p></li><li><p>IDEAYA BIOSCIENCES INC - TARGETS CLINICAL DATA UPDATE FOR IDE849 AND IDE161 IN H2 2026</p></li></ul><p>Source text: <span>ID:nPn2gvj4Wa</span></p><p>Further company coverage: <span>IDYA.O</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-Ideaya Biosciences Announces First-Patient-In For Phase 1 Combination Study Of Ide849, Dll3 Top1 Adc, And Ide161, Parg Inhibitor, In Dll3 Upregulated Solid Tumor Indications, Including Sclc, Nets, Necs, And Melanoma</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-Ideaya Biosciences Announces First-Patient-In For Phase 1 Combination Study Of Ide849, Dll3 Top1 Adc, And Ide161, Parg Inhibitor, In Dll3 Upregulated Solid Tumor Indications, Including Sclc, Nets, Necs, And Melanoma\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-03-30 21:09</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-Ideaya Biosciences Announces First-Patient-In For Phase 1 Combination Study Of Ide849, Dll3 Top1 Adc, And Ide161, Parg Inhibitor, In Dll3 Upregulated Solid Tumor Indications, Including Sclc, Nets, Necs, And Melanoma</title></head><body><p><span>March 30 (Reuters)</span><span> - </span><a href=\"https://laohu8.com/S/IDYA\">IDEAYA Biosciences</a> Inc <span>IDYA.O</span>:</p><ul><li><p>IDEAYA BIOSCIENCES ANNOUNCES FIRST-PATIENT-IN FOR PHASE 1 COMBINATION STUDY OF IDE849, DLL3 TOP1 ADC, AND IDE161, PARG INHIBITOR, IN DLL3 UPREGULATED SOLID TUMOR INDICATIONS, INCLUDING SCLC, NETS, NECS, AND MELANOMA</p></li><li><p>IDEAYA BIOSCIENCES INC - TARGETS CLINICAL DATA UPDATE FOR IDE849 AND IDE161 IN H2 2026</p></li></ul><p>Source text: <span>ID:nPn2gvj4Wa</span></p><p>Further company coverage: <span>IDYA.O</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260330:nTUABXCWR3:1","article_id":"2623348717","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2623348717","pubTimestamp":1774876159,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BRIEF-Ideaya Biosciences Announces First-Patient-In For Phase 1 Combination Study Of Ide849, Dll3 Top1 Adc, And Ide161, Parg Inhibitor, In Dll3 Upregulated Solid Tumor Indications, Including Sclc, Net","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","IDYA":"IDEAYA Biosciences"},"translate_title":"简介-Ideaya Biosciences宣布DLL3 TOP1 ADC IDE849和Parg抑制剂Ide161的1期联合研究的首例患者入组，用于Dll3上调的实体瘤适应症，包括Sclc、Nets、NEC和黑色素瘤","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"IDYA":0.9},"content_text":"BRIEF-Ideaya Biosciences Announces First-Patient-In For Phase 1 Combination Study Of Ide849, Dll3 Top1 Adc, And Ide161, Parg Inhibitor, In Dll3 Upregulated Solid Tumor Indications, Including Sclc, Nets, Necs, And MelanomaMarch 30 (Reuters) - IDEAYA Biosciences Inc IDYA.O:IDEAYA BIOSCIENCES ANNOUNCES FIRST-PATIENT-IN FOR PHASE 1 COMBINATION STUDY OF IDE849, DLL3 TOP1 ADC, AND IDE161, PARG INHIBITOR, IN DLL3 UPREGULATED SOLID TUMOR INDICATIONS, INCLUDING SCLC, NETS, NECS, AND MELANOMAIDEAYA BIOSCIENCES INC - TARGETS CLINICAL DATA UPDATE FOR IDE849 AND IDE161 IN H2 2026Source text: ID:nPn2gvj4WaFurther company coverage: IDYA.O ((Reuters.Briefs@thomsonreuters.com;))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":true,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.40.0","shortVersion":"4.40.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2623348717","isCrawlerRequest":true}